Inventiva S.A.
NASDAQ:IVABiotechnology
Healthcare
$3.39 +0.42%
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
52W Low $2.85High $7.98
Volume 3.54M
Average 0.45M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$100.98M
FY 2025 · Annual
Investing Cash Flow
-$127.93M
FY 2025 · Annual
Financing Cash Flow
$232.00M
FY 2025 · Annual
+59.4% YoYCash Flow Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Depreciation & Amortization | (1.29M) | 1.7M | 2.6M | 5.2M | 3.22M |
| Deferred Income Tax | (3.27M) | (5.26M) | (4.74M) | (4.8M) | (2.3M) |
| Stock-Based Compensation | 2.09M | 2.22M | 3.97M | 3.58M | 26.77M |
| Change in Working Capital | 979K | 5.71M | 17.31M | 1.68M | 6.42M |
| Accounts Receivables | (5.32M) | 3.84M | (5.84M) | 2.81M | 816.45K |
| Inventory | (72K) | 19K | (44K) | 417K | 0 |
| Accounts Payables | 7.6M | 3.54M | 20M | 0 | 2.46M |
| Other Working Capital | (1.23M) | (1.69M) | 3.19M | (1.54M) | 3.15M |
| Other Non-Cash Items | 3.5M | 4.98M | 9.68M | 92.63M | 205.07M |
| Operating Cash Flow | (47.63M) | (44.93M) | (81.61M) | (85.93M) | (100.98M) |
| Capital Expenditures | (534K) | (561K) | (540K) | (333K) | (237.26K) |
| Acquisitions (Net) | 89K | 41K | 0 | 0 | 0 |
| Purchases of Investments | (1.35M) | (1K) | (8.3M) | 0 | (127.69M) |
| Sales of Investments | (89K) | 9.39M | 978K | 9.08M | 0 |
| Other Investing Activities | 90K | 1K | 131K | 75.72K | (1K) |
| Investing Cash Flow | (1.79M) | 8.87M | (7.73M) | 8.75M | (127.93M) |
| Debt Repayment | (28K) | 28.44M | (4.1M) | 19.92M | (5.98M) |
| Common Stock Issued | 25.48M | 8.83M | 28.08M | 57.34M | 237.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (17.73K) | (772.47K) | 5.1M | 68.33M | 236.98K |
| Financing Cash Flow | 25.45M | 37.27M | 29.08M | 145.59M | 232M |
| Effect of Forex Changes | 4.84M | (1.03M) | 445K | 1.24M | 11.08M |
| Net Change in Cash | (19.13M) | 183K | (59.82M) | 69.65M | 14.17M |
| Free Cash Flow | (48.16M) | (45.49M) | (82.15M) | (86.26M) | (101.22M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$340.2M
+ D&A$3.2M
+ Stock-Based Comp$26.8M
- Deferred Tax-$2.3M
+ Working Capital$6.4M
+ Other Non-Cash$205.1M
= Operating Cash Flow-$101.0M
- Capex-$237.3K
= Free Cash Flow-$101.2M
Analysis
FY2025 free cash flow is -$101.2M. FCF conversion is 29.8% of net income. Operating cash flow was -$101.0M, with capex of -$237.3K. The largest bridge item is Other Non-Cash at $205.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 6-K | 6-K filing | Oct 6, 2026 | |
| 6-K | 6-K filing | Sep 28, 2026 | |
| 6-K | 6-K filing | Sep 3, 2026 | |
| 6-K | 6-K filing | Sep 1, 2026 |
Does IVA generate free cash flow?
Inventiva S.A. (IVA) generated -$101.22M of free cash flow in fiscal 2025.
How much operating cash flow does IVA produce?
Operating cash flow was -$100.98M, before capital expenditures of $237,255.00.
Continue the stock analysis
Jump to another research area for this company.